<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" dstore:dataset="cepi-998" dstore:index="2" hierarchy="1" humanitarian="0" iati-activities:generated-datetime="2021-03-29T10:11:10+00:00" iati-activities:version="2.03" last-updated-datetime="2021-03-29T10:11:10+00:00" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>NO-BRC-917687811-CEPI_01</iati-identifier>
  <reporting-org ref="NO-BRC-917687811" type="30">
   <narrative xml:lang="EN">Coalition for Epidemic Preparedness innovations</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Research and development of vaccines</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">CEPI 1.0
CEPI&#x2019;s mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. The budget presented in this activity includes all investments + operating expenses and financial costs. 
&#x2022; CFP1 on priority pathogens for EIDs: Launched January 2017 for the diseases Lassa, Nipah and MERS. The decision on priority diseases departed from pathogens identified by the WHO Blueprint for Action, followed by an in-depth assessment by the SAC. In recommending priority diseases to the CEPI Board, the SAC applied criteria related to 1) public health impact (potential of outbreak, transmissibility, burden of disease) and 2) feasibility (current scientific knowledge, pipeline candidates available). 
&#x2022; CFP2 on platform technologies: Launched October 2017 to enable rapid vaccine development against both known and unknown pathogens that trigger infections with epidemic potential. A requirement is to produce sufficient vaccine doses to impact an emerging outbreak and that the platform demonstrates versatility one of the priority pathogens from the WHO Blueprint list. 
&#x2022; CEPI&#x2019;s third call for proposals (CfP3i) was for the development of human vaccines against Rift Valley fever and Chikungunya diseases. Rift Valley fever disease is included among the WHO R&amp;D Blueprint list of priority pathogens in 2018, while Chikungunya is deemed to present a major public health risk where further R&amp;D is needed. The call for proposals closed on March, 2019. 
&#x2022; In addition to the vaccine development projects, CEPI has made several investments within the Enabling Science area, like biological standards and assays, data collection &amp; scientific research, epidemiology and clinical development. 
&#x2022; A global consortium is supporting the Government of the Democratic Republic of the Congo (DRC) to introduce a second investigational Ebola vaccine as part of ongoing efforts to contain the outbreak in eastern DRC. The large-scale clinical trial, sponsored by the London School of Hygiene &amp; Tropical Medicine (LSHTM), is designed to help prevent the spread of the epidemic, the second worst in history, beyond the currently affected areas in eastern DRC, and if possible gather crucial information about the effectiveness of the vaccine to be better prepared to fight Ebola in the future.

COVID-19
In 2020 CEPI launched a new call for proposals to develop vaccines against novel coronavirus, COVID-19. COVID-19 data is included in a separate IATI activity. 

CEPI 2.0
A detailed implementation plan for the CEPI strategy for 2022-26 will be developed in 2021, building from an assessment of implications and risks related to the new strategy and will include the updated governance structure, organizational arrangements, and decision-making processes to guide the implementation of the strategy starting in 2022. The forecasted financial needs for the 2022-2026 business cycle are in the range of US$ 3.5 to 4 billion. The forecast in this IATI activity, includes an estimate of the spending until the end of 2026.</narrative>
  </description>
  <participating-org activity-id="DAC-1601-OPP1180343" ref="DAC-1601" role="1" type="60">
   <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">Wellcome Trust</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Norway</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Japan</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Belgium</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Australia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of the United Kingdom</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International AIDS Vaccine Initiative</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">IDT biologica</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Inovio Pharmaceuticals</narrative>
  </participating-org>
  <participating-org ref="GB-UKPRN-10007774" role="4" type="80">
   <narrative xml:lang="EN">University of Oxford, The</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Themis Bioscience</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Tokyo</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">CureVac</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Imperial College</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Queensland</narrative>
  </participating-org>
  <participating-org ref="US-EIN-91-1157127" role="4" type="21">
   <narrative xml:lang="EN">PATH</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Aurobindo</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Public Health Vaccines</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Emergent BioSolutions</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Colorado State University</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International Vaccines Institute</narrative>
  </participating-org>
  <participating-org role="4" type="90">
   <narrative xml:lang="EN">Larissa</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Valneva</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">BNITM</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Brighton Collaboration</narrative>
  </participating-org>
  <participating-org role="4" type="11">
   <narrative xml:lang="EN">INRB</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">LSHTM</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">MSF France</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Antwerpen</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Epicentre</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Dalhousie Univesity</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">FIND</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Janssen</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">NIBSC</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Tulane University</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">CDV Mali</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of North-Carolina</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Nigeria NCDC</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Benin FORS</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Ethiopia</narrative>
  </participating-org>
  <participating-org role="1" type="90">
   <narrative xml:lang="EN">European Commission</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">Vulcan</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Canada</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Germany</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Denmark</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Finland</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Indonesia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Netherlands</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Singapore</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of South Korea</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Switzerland</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Saudi Arabia</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Taskforce for Global Health</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Queensland</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-09098104" role="4" type="80">
   <narrative xml:lang="EN">Wageningen University &amp; Research - Stichting Wageningen Research</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Pittsburgh</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Integrum</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Robert Koch Institute</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">P-95</narrative>
  </participating-org>
  <participating-org role="1" type="15">
   <narrative xml:lang="EN">United States Agency for International Development</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2016-08-30" type="2">
   <narrative xml:lang="EN">Company created in 2016. First disbursement to awardees made in 2018</narrative>
  </activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">CEPI Secretariat</narrative>
   </organisation>
   <email>secretariat@cepi.net</email>
   <website>https://cepi.net/</website>
   <mailing-address>
    <narrative xml:lang="EN">Marcus Thranes gate 2, 0473 Oslo</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="1"></activity-scope>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">CEPI funds are invested in projects all over the globe. Allthough the companies that we fund may be located in HICs/MICs, the main benificiaries of the products we help develop will be developing countries.</narrative>
  </recipient-region>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-31"></period-end>
   <value currency="USD" value-date="2018-12-31">131300000</value>
  </budget>
  <budget status="1" type="2">
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-31"></period-end>
   <value currency="USD" value-date="2020-03-09">254700000</value>
  </budget>
  <budget status="1" type="2">
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-31"></period-end>
   <value currency="USD" value-date="2021-03-29">253254486</value>
  </budget>
  <budget status="1" type="2">
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-31"></period-end>
   <value currency="USD" value-date="2021-03-29">369891538</value>
  </budget>
  <budget status="1" type="2">
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-31"></period-end>
   <value currency="USD" value-date="2021-03-29">437284815</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2024-01-01"></period-start>
   <period-end iso-date="2024-12-31"></period-end>
   <value currency="USD" value-date="2021-03-23">992218540</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2025-01-01"></period-start>
   <period-end iso-date="2025-12-31"></period-end>
   <value currency="USD" value-date="2021-03-23">633880134</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2026-01-01"></period-start>
   <period-end iso-date="2026-12-31"></period-end>
   <value currency="USD" value-date="2021-03-23">200224932</value>
  </budget>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2021-01-31"></transaction-date>
   <value currency="USD" value-date="2021-01-31">4000000</value>
   <provider-org type="15">
    <narrative xml:lang="EN">United States Agency for International Development</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2021-02-28"></transaction-date>
   <value currency="USD" value-date="2021-02-28">24307244</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Germany</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2021-02-28"></transaction-date>
   <value currency="USD" value-date="2021-02-28">2622459</value>
   <provider-org type="60">
    <narrative xml:lang="EN">Wellcome Trust</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-31"></transaction-date>
   <value currency="USD" value-date="2017-12-31">2232172</value>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2017</narrative>
   </description>
   <flow-type code="10"></flow-type>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <value currency="USD" value-date="2019-12-31">121799995</value>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2019</narrative>
   </description>
   <flow-type code="10"></flow-type>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-01-31"></transaction-date>
   <value currency="USD" value-date="2020-01-31">15099</value>
   <provider-org type="60">
    <narrative xml:lang="EN">Wellcome Trust</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="USD" value-date="2020-03-31">22602275</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Norway</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-03-31"></transaction-date>
   <value currency="USD" value-date="2020-03-31">11747016</value>
   <provider-org type="10">
    <narrative xml:lang="EN">The United Kingdom</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-04-30"></transaction-date>
   <value currency="USD" value-date="2020-04-30">60999925</value>
   <provider-org type="60">
    <narrative xml:lang="EN">Wellcome Trust</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-05-31"></transaction-date>
   <value currency="USD" value-date="2020-05-31">20000000</value>
   <provider-org type="60">
    <narrative xml:lang="EN">Bill and Melinda Gates Foundation</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-05-31"></transaction-date>
   <value currency="USD" value-date="2020-05-31">1447399</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Denmark</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-05-31"></transaction-date>
   <value currency="USD" value-date="2020-05-31">2056871</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Switzerland</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-05-31"></transaction-date>
   <value currency="USD" value-date="2020-05-31">139</value>
   <provider-org type="90">
    <narrative xml:lang="EN">Other investors</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-06-30"></transaction-date>
   <value currency="USD" value-date="2020-06-30">599984</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Singapore</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-05-31"></transaction-date>
   <value currency="USD" value-date="2020-05-31">1084714</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Finland</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-07-31"></transaction-date>
   <value currency="USD" value-date="2020-07-31">5704000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Germany</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-07-31"></transaction-date>
   <value currency="USD" value-date="2020-07-31">25000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Japan</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-07-31"></transaction-date>
   <value currency="USD" value-date="2020-07-31">231963</value>
   <provider-org type="90">
    <narrative xml:lang="EN">Other investors</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-08-31"></transaction-date>
   <value currency="USD" value-date="2020-08-31">299984</value>
   <provider-org type="90">
    <narrative xml:lang="EN">Other investors</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-09-30"></transaction-date>
   <value currency="USD" value-date="2020-09-30">10662242</value>
   <provider-org type="15">
    <narrative xml:lang="EN">European Commission</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-11-30"></transaction-date>
   <value currency="USD" value-date="2020-11-30">1172743</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Netherlands</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-11-30"></transaction-date>
   <value currency="USD" value-date="2020-11-30">97273</value>
   <provider-org type="90">
    <narrative xml:lang="EN">Other investors</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-10-31"></transaction-date>
   <value currency="USD" value-date="2020-10-31">1000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Saudi Arabia</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-12-31"></transaction-date>
   <value currency="USD" value-date="2020-12-31">3000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of South Korea</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2020-11-30"></transaction-date>
   <value currency="USD" value-date="2020-11-30">1000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Indonesia</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2017-12-31"></transaction-date>
   <value currency="USD" value-date="2017-12-31">82170677</value>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2017</narrative>
   </description>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <value currency="USD" value-date="2019-12-31">211902690</value>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2019</narrative>
   </description>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-12-31"></transaction-date>
   <value currency="USD" value-date="2018-12-31">53244507</value>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2018</narrative>
   </description>
   <flow-type code="10"></flow-type>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-31"></transaction-date>
   <value currency="USD" value-date="2020-12-31">100642674</value>
   <description>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2020</narrative>
   </description>
   <provider-org>
    <narrative xml:lang="EN">All outgoing investments + Operating expenses and financial costs 2020</narrative>
   </provider-org>
   <flow-type code="10"></flow-type>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2018-12-31"></transaction-date>
   <value currency="USD" value-date="2018-12-31">113339500</value>
   <description>
    <narrative xml:lang="EN">All incoming funds received in 2018</narrative>
   </description>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://cepi.net/wp-content/uploads/2019/05/Programme-Document_April-2019.pdf">
   <title>
    <narrative xml:lang="EN">Programme Document</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">The purpose of this document is to provide coherent overview about this direction as it relates to CEPI&#x2019;s strategic objectives and operations</narrative>
   </description>
   <category code="A02"></category>
   <language code="EN"></language>
   <document-date iso-date="2019-04-30"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://cepi.net/wp-content/uploads/2019/05/CEPI-Progress-Report_2018.pdf">
   <title>
    <narrative xml:lang="EN">Progress Report 2018</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">This document provides an overview of CEPI&apos;s activities and achievements in 2018</narrative>
   </description>
   <category code="A08"></category>
   <language code="EN"></language>
   <document-date iso-date="2019-03-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://aidstream.org/files/documents/Other-investors_core-pool_as-of-Dec-30,-2020-20210303050355.pdf">
   <title>
    <narrative xml:lang="EN">Incoming funds from Other investors_core pool</narrative>
   </title>
   <category code="A04"></category>
   <language code="EN"></language>
   <document-date iso-date="2021-02-28"></document-date>
  </document-link>
 </iati-activity>
</iati-activities>
